Fasting at night may cut cancer risk in people with blood disorder precursors
NCT ID NCT05565638
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting program or a healthy lifestyle education group for 4 months. The main goal was to see changes in body composition, with secondary measures of blood markers related to cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prolonged nightly fasting (behavioral intervention)
What this could lead to
If this works, it could point toward a simple lifestyle change—extending the nightly fast—to help prevent blood cancer in people with early warning signs.
What could go wrong
This is a very small, early study (23 participants) testing weight loss, not cancer directly. The fasting intervention may be hard to stick with long-term, and any cancer benefit is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States